BioStem Technologies, Inc. (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allograft products, announced it will release its first quarter 2026 financial results on Thursday, May 14, 2026, and will host a conference call and webcast at 4:30 PM ET that same day. The webcast will feature an overview of the quarter from BioStem Technologies management, offering stakeholders insights into the company's financial performance and operational developments.
To participate in the conference call, attendees can dial the North America toll-free number at (800) 715-9871 or the international toll number at +1 (646) 307-1963, using conference ID 9695874. A live webcast will also be available at https://events.q4inc.com/attendee/844730655. The company encourages interested parties to register in advance via the provided link.
BioStem Technologies focuses on developing, manufacturing, and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages proprietary processing technologies, including BioRetain®, CryoTek®, and SteriTek®, designed to preserve the natural properties of these tissues for clinical use. Its allografts are utilized by clinicians across various specialties, and the company maintains a growing product portfolio, expanding clinical research initiatives, and a national commercial footprint.
The announcement of the financial results and conference call comes as BioStem continues to advance its position in the regenerative medicine sector. The company's quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (AATB) and are established in compliance with current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP). BioStem's product lines include Neox®, Clarix®, VENDAJE®, and American Amnion™.
For investors and industry observers, the upcoming financial results will provide key metrics on the company's revenue growth, operational efficiency, and market expansion. The regenerative medicine market has seen increasing demand for advanced wound care and surgical solutions, and BioStem's allograft products are positioned to address these needs. The conference call may offer updates on new product developments, clinical trial progress, and strategic partnerships.
BioStem Technologies is publicly traded under the ticker symbol BSEM on the OTC market. The latest news and updates relating to the company are available in its newsroom at https://tinyurl.com/bsemnewsroom. The company also maintains an email distribution list for updates and can be followed on social media platforms such as X and LinkedIn.
The first quarter 2026 results will cover the period ending March 31, 2026. Investors and analysts will be watching for signs of continued growth in revenue and product adoption, as well as any updates on regulatory or reimbursement developments that could impact the company's trajectory. The webcast is scheduled to begin at 4:30 PM ET on May 14, 2026.
